logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11485773 B1

PDFFull Text
Date of Patent:
Nov. 01, 2022

Filed:

Mar. 13, 2020

Protease inhibitor:protease sensitive expression system and method improving the therapeutic activity and specificity of proteins and phage and phagemids delivered by bacteria

Applicant:

David Gordon Bermudes, Woodland Hills, CA (US);

Inventor:

David Gordon Bermudes, Woodland Hills, CA (US);

Assignee:

Other;

Attorneys:

Hoffberg & Associates

Steven M. Hoffberg

Primary Examiner:

Karen Cochrane Carlson

Int. Cl.
CPC ...
C07K 14/81 (2006.01); C12N 9/02 (2006.01); C07K 14/005 (2006.01); C07K 14/245 (2006.01); C12N 15/113 (2010.01); A61K 38/55 (2006.01); C12N 15/74 (2006.01); A61K 38/00 (2006.01); C12N 9/22 (2006.01); A61K 35/74 (2015.01); A61K 38/16 (2006.01);
U.S. Cl.
CPC ...
C07K 14/81 (2013.01); A61K 38/00 (2013.01); A61K 38/005 (2013.01); A61K 38/55 (2013.01); C07K 14/005 (2013.01); C07K 14/245 (2013.01); C12N 9/0071 (2013.01); C12N 9/22 (2013.01); C12N 15/1135 (2013.01); C12N 15/1137 (2013.01); C12N 15/74 (2013.01); A61K 35/74 (2013.01); A61K 38/164 (2013.01); C07K 2319/00 (2013.01); C07K 2319/02 (2013.01); C07K 2319/50 (2013.01); C07K 2319/55 (2013.01); C12N 2310/14 (2013.01); C12N 2310/141 (2013.01); Y02A 50/30 (2018.01);
Abstract

A genetically engineered live bacterium which is adapted to selectively replicate in and colonize a selected tissue type within the mammal, and concurrently produce within the selected tissue type at least one protease-sensitive cytotoxic molecule which is degradable by proteases within the selected tissue type, and at least one protease inhibitor peptide to inhibit the proteases within the selected tissue type from proteolytically degrading the protease sensitive cytotoxic molecule. The combination results in higher concentrations of the cytotoxic molecule local to the colonization, while permitting protease degradation of the cytotoxic molecule further away from the colonization.

Find Patent Forward Citations

Loading…